Quick Answer
Quoin Pharmaceuticals, Ltd. reported Total Revenue of $0.00 for fiscal year 2021.
Quoin Pharmaceuticals, Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | $0.00 | $0.00 |
| Revenue (ASC 606) | — | — | — | — | $0.00 | $0.00 |
| Net Income | -$15.80M -76.3% |
-$8.96M -3.2% |
-$8.69M +7.4% |
-$9.38M +56.3% |
-$21.46M -924.3% |
-$2.10M -34.3% |
| Diluted EPS | — | — | — | — | -$0.01 +98.6% |
-$0.70 -34.6% |
| Total Assets | $20.39M +29.8% |
$15.71M +29.1% |
$12.17M -15.8% |
$14.46M +54.5% |
$9.36M +579.1% |
$1.38M -93.5% |
| Cash and Equivalents | $3.82M +5.4% |
$3.62M +50.9% |
$2.40M -16.1% |
$2.86M -61.8% |
$7.48M +2210.7% |
$323.8K |
| Stockholders Equity | $13.12M +42.5% |
$9.20M +62.5% |
$5.66M -23.5% |
$7.41M +1027.3% |
$657.0K +109.9% |
-$6.61M -46.4% |
| R&D Expense | $9.80M +172.1% |
$3.60M +8.9% |
$3.31M +23.8% |
$2.67M +71.0% |
$1.56M +540.1% |
$244.2K +434.8% |
| Shares Outstanding | 52.44M +486.1% |
8.95M +806.4% |
987,220 +144.4% |
403,887 -100.0% |
3.35B +179.2% |
1.20B |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$3.95M | -68.0% | -6.8% |
| Total Assets | September 30, 2025 | $6.42M | -43.6% | -27.9% |
| Cash and Equivalents | September 30, 2025 | $1.83M | -41.3% | +9.7% |
| Stockholders Equity | September 30, 2025 | -$1.21M | -122.3% | -147.6% |
| R&D Expense | September 30, 2025 | $2.28M | +111.3% | +11.2% |
| Shares Outstanding | September 30, 2025 | 20.59M | +307.7% | +0.0% |
- Quoin Pharmaceuticals, Ltd. reported Total Revenue of $0.00 for fiscal year 2021.
- Quoin Pharmaceuticals, Ltd. reported Revenue (ASC 606) of $0.00 for fiscal year 2021.
- Quoin Pharmaceuticals, Ltd. reported Net Income of -$15.80 million for fiscal year 2025.
- Quoin Pharmaceuticals, Ltd. showed a decrease of -76.3% in Net Income compared to the prior fiscal year.
- Quoin Pharmaceuticals, Ltd. reported Diluted EPS of $0.01 per share (loss) for fiscal year 2021.
- Quoin Pharmaceuticals, Ltd. showed an increase of +98.6% in Diluted EPS compared to the prior fiscal year.
- Quoin Pharmaceuticals, Ltd. reported Total Assets of $20.39 million for fiscal year 2025.
- Quoin Pharmaceuticals, Ltd. showed an increase of +29.8% in Total Assets compared to the prior fiscal year.
- Quoin Pharmaceuticals, Ltd. reported Cash and Equivalents of $3.82 million for fiscal year 2025.
- Quoin Pharmaceuticals, Ltd. showed an increase of +5.4% in Cash and Equivalents compared to the prior fiscal year.
- Quoin Pharmaceuticals, Ltd. reported Stockholders Equity of $13.12 million for fiscal year 2025.
- Quoin Pharmaceuticals, Ltd. showed an increase of +42.5% in Stockholders Equity compared to the prior fiscal year.
- Quoin Pharmaceuticals, Ltd. reported R&D Expense of $9.80 million for fiscal year 2025.
- Quoin Pharmaceuticals, Ltd. showed an increase of +172.1% in R&D Expense compared to the prior fiscal year.
- Quoin Pharmaceuticals, Ltd. reported Shares Outstanding of 52.44 million shares for fiscal year 2025.
- Quoin Pharmaceuticals, Ltd. showed an increase of +486.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: